Aug 10, 2023 10:40am EDT ProPhase Labs Announces Updated Conference Call Dial-in Information for Thursday August 10, 2023 at 11:00 a.m. Eastern Time for Second Quarter 2023 Financial Results Call.
Aug 10, 2023 8:00am EDT ProPhase Labs Announces Financial Results for the Three Months Ended June 30, 2023
Aug 03, 2023 8:00am EDT ProPhase Labs Teams up with Certis Oncology to Accelerate Development of Novel Linebacker Compound
Aug 02, 2023 8:00am EDT ProPhase Labs to Host Second Quarter 2023 Financial Results Conference Call on Thursday, August 10, 2023 at 11:00 a.m. Eastern Time
Jun 29, 2023 8:00am EDT Navidea Biopharmaceuticals Rejects ProPhase Labs Offer To Acquire Certain Assets of Navidea
Jun 22, 2023 8:30am EDT ProPhase Labs Inc. Sets the Course for Expansion into the MENA Region with Cutting-Edge Genomic and Diagnostics Technologies
Jun 07, 2023 8:00am EDT ProPhase Labs to Present at the Diamond Equity Research Emerging Growth Invitational on Tuesday, June 13, 2023
Jun 01, 2023 8:30am EDT ProPhase Labs’ Cancer Therapeutic, Linebacker-1, pre-clinical studies with Dana Farber/Harvard Cancer Institute demonstrate impressive utility and move into next phase of testing
May 11, 2023 8:00am EDT ProPhase Labs Announces Financial Results for the Three Months Ended March 31, 2023
May 08, 2023 8:30am EDT ProPhase Labs hires Dr. Matthew Halpert to Drive Company’s Key Therapeutic and Diagnostic Oncology Programs
